Filing Analysis
Arcturus Therapeutics Holdings Inc. reported the results of its 2026 annual meeting of stockholders held on June 5, 2026. Stockholders elected the Board of Directors, approved executive compensation on an advisory basis, and ratified the appointment of Deloitte & Touche LLP as the independent auditor.
📋 Key Facts
- Annual meeting held on June 5, 2026, with a quorum of 21,435,189 shares present out of 28,423,069 entitled to vote.
- Eight directors were elected to the Board: Dr. Peter Farrell, Joseph E. Payne, James Barlow, Dr. Edward W. Holmes, Dr. Magda Marquet, Dr. Jing L. Marantz, Dr. John Markels, and Dr. Moncef Slaoui.
- The 'say-on-pay' advisory resolution for executive compensation was approved with 15,254,240 votes in favor.
- Deloitte & Touche LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with 21,378,017 votes in favor.
Arcturus Therapeutics appointed Dennis Mulroy as its new Chief Financial Officer effective May 1, 2026, while simultaneously reporting Q1 2026 financial results. Mulroy succeeds Joe Roberts, who had been serving as interim principal financial officer since December 2025.
🚩 Red Flags
- Multiple 8-K items (2.02, 5.02, 7.01) filed simultaneously.
- The company has been operating with an interim principal financial officer since December 2025.
📋 Key Facts
- Dennis Mulroy (71) appointed CFO with a base salary of $520,000 and a 40% target bonus.
- Mulroy was granted 100,000 stock options vesting over four years.
- Joe Roberts will continue as the Company’s Controller and interim principal accounting officer.
- The filing includes Q1 2026 financial results and updates on the ARCT-032 and ARCT-810 clinical programs.
- Mulroy previously served as CFO of AnaptysBio, Inc. and La Jolla Pharmaceutical Company.
Arcturus Therapeutics announced its financial results for the fourth quarter and full year ended December 31, 2025, and provided a corporate update on its clinical pipeline and strategic partnerships.
📋 Key Facts
- Reported financial results for the fiscal year ended December 31, 2025.
- Provided clinical updates on ARCT-032, including plans for a Phase 2, 12-week study.
- Discussed regulatory strategy for ARCT-810, including upcoming Type C meetings with regulators.
- Highlighted ongoing collaborations with CSL Seqirus for COVID-19 and flu programs.
- Confirmed ongoing development of a self-amplifying mRNA pandemic influenza vaccine under contract with BARDA.
- Management indicated that general and administrative expenses are expected to decrease slightly.